Vermillion (VRML) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vermillion Reports First Quarter 2016 Results
May 16, 2016 4:01 PM EDTAUSTIN, Texas, May 16, 2016 /PRNewswire/ --Â Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the first quarter ended March 31, 2016.
Valerie Palmieri, President and CEO of Vermillion, Inc., stated, "The first quarter marked a number of accomplishments, and we are on track with our 2016 commercial plan. The FDA's clearance of Overa and the publication of our peer-reviewed clinical utility study regarding OVA1 were two of our major accomplishments in the first quarter. In addition, we launched our "Direct-to-Women" education campaign and started... More
